Kathleen M. Carroll PhD

Albert E. Kent Professor of Psychiatry; Director of Psychosocial Research, Division of Addictions; Principal Investigator, Psychotherapy Development Center for Drug Abuse


Departments & Organizations

DAHRS

Psychiatry: Division of Substance Abuse | Substance Abuse Research | Psychotherapy Development Center | Psychology Section

Biography

Dr. Kathleen M. Carroll graduated summa cum laude from Duke University, received her Ph.D. in clinical psychology in 1988 from the University of Minnesota, and completed her pre-doctoral training at the Yale University School of Medicine’s Division of Substance Abuse, where she was promoted to Professor in 2002. Since 1994 she has served as Scientific Director of the Center for Psychotherapy Development at Yale, NIDA’s only Center devoted to behavioral therapies research, and since 1999 she has been Principal Investigator of the New England Node of the National Institute on Drug Abuse’s Clinical Trials Network. An ISI Thompson ISI Highly Cited Researcher, Dr. Carroll is the author of over 220 peer-reviewed publications as well as numerous chapters and books.

Her research has focused on the development and evaluation of behavioral treatments and combinations of behavioral therapies and pharmacotherapies, with an emphasis on improving the quality and rigor of clinical efficacy research in the addictions. Dr. Carroll received a NIH MERIT (Method to Extend Research in Time) in 2003 for her work on developing computer-assisted training in cognitive-behavioral therapy. Dr. Carroll served as President of the American Psychological Association’s Division 50 (Addictions) from 2002-2005 and received the Divisions’ Distinguished Scientific Contributions to Education and Training Award in 2005.

Education

  • B.S., Duke University , 1980
  • Ph.D., University of Minnesota , 1988

Selected Publication

  • Carroll, K.M., Kiluk, B.D., Nich, C., DeVito, E.E., Decker, S., LaPaglia, D., Duffey, D., Babuscio, T.A. & Ball, S.A. (2014). Towards empirical identification of a reliable and clinically meaningful indicator of treatment outcome for illicit drug use. Drug and Alcohol Dependence, 137, 3-19

Latest Honor and Recognition

  • Highly Cited Researcher(2008) , Thompson ISI